Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Nathan P. Horvat"'
Publikováno v:
Cureus.
Publikováno v:
Cancers
Cancers, Vol 12, Iss 2278, p 2278 (2020)
Cancers, Vol 12, Iss 2278, p 2278 (2020)
Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by the upregulation of the Janus kinase (JAK)—signal transducer and activator of transcription (STAT) pathway with associated extramedullary hematopoiesis and a high burden of disease-r
Autor:
Virginia Olivia Volpe, Nicole D. Vincelette, Onyee Chan, Chetasi Talati, Kendra Sweet, Andrew T. Kuykendall, Constantine Logothetis, Rami S. Komrokji, Gregoire Calon, Nathan P. Horvat, David A. Sallman, Eric Padron, Ling Zhang, Seongseok Yun
Publikováno v:
Blood. 138:2377-2377
Background In AML, IDH1/2 somatic mutations can be frequent in patients at about 20%. Physiologically, IDH1/2 catalyze isocitrate conversion to alpha-ketoglutarate (α-KG). α-KG is an activating co-factor for ten-eleven translocation 2 (TET2), an im
Autor:
Javier Pinilla, Lubomir Sokol, Bijal D. Shah, Sameh Gaballa, Julio C. Chavez, Hayder Saeed, Tony Kurian, Constantine Logothetis, Nathan P. Horvat, Leidy Isenalumhe, Celeste M. Bello
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S405
Context/Objective Marginal zone lymphoma (MZL) is an indolent non-Hodgkin lymphoma (NHL) accounting for 8–12% of NHL. Extra-nodal MZL (EMZL) is the most common subgroup, comprising ~70% of cases. Bendamustine and rituximab (BR) are commonly used as
Autor:
Ling Zhang, Kendra Sweet, Nathan P. Horvat, Virginia O. Volpe, Eric Padron, Nicole D. Vincelette, Chetasi Talati, Seongseok Yun, Gregoire Calon, Onyee Chan, Constantine Logothetis, David A. Sallman, Jeffrey E. Lancet, Rami S. Komrokji, Andrew T. Kuykendall
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S212
Autor:
Eric Padron, David A. Sallman, Najla Al Ali, Rami S. Komrokji, Nathan P. Horvat, Chetasi Talati, Kendra Sweet, Onyee Chan, Jeffrey E. Lancet, Andrew T. Kuykendall
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S358
Context: Myelofibrosis (MF) rarely presents in young patients. Young patients with MF enjoy a more indolent disease course and a lower incidence of adversely prognostic clinical and genomic variables. Analysis of this population may identify patient-
Autor:
Andrew T. Kuykendall, Virginia O. Volpe, Rami S. Komrokji, Ling Zhang, Constantine Logothetis, Eric Padron, Jeffrey E. Lancet, Nathan P. Horvat, Gregoire Calon, Seongseok Yun, Nicole D. Vincelette, Onyee Chan, Kendra Sweet, David A. Sallman, Chetasi Talati
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S286
Context: Clinical trials of IDH1/2 inhibitors demonstrated promising outcomes in IDH1/2mut AML patients. However, a substantial fraction of patients fail to respond to IDH1/2 inhibitors in AML. Recent preclinical studies have shown MYC prevents the n
Autor:
Nathan P. Horvat, Rami Komrokji, Najla Al Ali, Chetasi Talati, Eric Padron, David Sallman, Kendra Sweet, Onyee Chan, Jeffrey Lancet, Andrew T. Kuykendall
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S232
Autor:
Kendra Sweet, Gregoire Calon, David A. Sallman, Rami S. Komrokji, Onyee Chan, Ling Zhang, Virginia O. Volpe, Andrew T. Kuykendall, Constantine Logothetis, Eric Padron, Nathan P. Horvat, Seongseok Yun, Chetasi Talati, Nicole D. Vincelette, Jeffrey E. Lancet
Publikováno v:
Journal of Clinical Oncology. 39:e19010-e19010
e19010 Background: Recent studies showed that IDH1/2 are frequently mutated in AML and that aberrant 2-HG elevation driven by the mutant IDH1/2 proteins plays a pivotal role in AML development. Subsequent clinical trials of IDH1/2 inhibitors demonstr
Autor:
Ross L. Levine, Chiara Conti, Lanzhu Yue, Eva Sahakian, Nathan P. Horvat, Amit Verma, John Powers, Narmin E. Amin, Afua A. Akuffo, Kenneth L. Wright, C. Gary Marshall, Pui Yee Ng, Ling Zhang, Javier Pinilla-Ibarz, Xiaozhang Zheng, John M. Koomen, Julia M.R. Billington, Zonghong Shao, Matthew Beatty, Lancia Darville, Christelle M. Colin, Pearlie K. Epling-Burnette, Eduardo M. Sotomayor, Que T. Lambert-Showers, Jennifer Y. Lee, Matthew W. Martin, Gary W. Reuther, Cem Murdun, H. Leighton Grimes, William E. Goodheart, Vasundhara Sharma
Publikováno v:
Blood
Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability and has been implicated in JAK2-driven diseases best exemplified by myeloproliferative neoplasms (MPNs